Physician profile
Vance Perry Lewis
NPI 1578978805
$5,500.09
in general payments reported to CMS, 2019-2025
21 companies · $3,015 in 2025
The $3,015 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $486 · 2020: $267 · 2021: $361 · 2022: $180 · 2023: $624 · 2024: $567 · 2025: $3,015.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,281 · Food and Beverage: $1,924.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,280.80 |
| Food and Beverage | $1,924.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $2,840.32 | 2019-2025 | Cvi Contact Lens, Clariti Contact Lens, Myday Contact Lens |
| Bausch & Lomb Americas INC. | $522.72 | 2022-2024 | Infuse, Miebo, Revive |
| Johnson & Johnson Vision Care, INC. | $430.88 | 2019-2021 | |
| Alcon Vision LLC | $364.91 | 2019-2025 | Dailies Total1, Total30, Precision 1 |
| Lumenis Be INC | $271.49 | 2023 | Optilight |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $223.77 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $128.95 | 2021 | |
| Shire North American Group INC | $120.00 | 2019 | |
| Harrow Eye, LLC | $116.58 | 2025 | Vevye |
| Abbvie INC. | $112.50 | 2023-2024 | |
| Tarsus Pharmaceuticals, INC. | $108.93 | 2024-2025 | Xdemvy |
| Rxsight INC | $47.69 | 2024 | Rxsight Injector Handpiece, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Glaukos Corporation | $44.96 | 2024 | Idose |
| Novartis Pharmaceuticals Corporation | $28.83 | 2023 | |
| Visioneering Technologies, INC. | $25.46 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optos, INC. | $24.75 | 2019 | |
| Sun Pharmaceutical Industries INC. | $21.57 | 2024 | |
| Dompe US, INC. | $20.05 | 2023 | Oxervate |
| Lkc Technologies, INC. | $18.84 | 2024 | |
| Johnson & Johnson Surgical Vision, INC. | $13.76 | 2019 | |
| Thea Pharma INC. | $13.13 | 2023 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vance Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.